Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer

Radium-223 dichloride ((223)Ra) is an α-emitter approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, but without visceral involvement. Despite being a life-prolonging therapy (LPT), (223)Ra remains underutilized. A large body of real-world evide...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Joe M., McKay, Rana R., Rahbar, Kambiz, Fizazi, Karim, George, Daniel J., Tombal, Bertrand, Schmall, Anja, Sandström, Per, Verholen, Frank, Shore, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812947/
https://www.ncbi.nlm.nih.gov/pubmed/36619649
http://dx.doi.org/10.3389/fmed.2022.1070392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812947/
https://www.ncbi.nlm.nih.gov/pubmed/36619649
http://dx.doi.org/10.3389/fmed.2022.1070392

Ejemplares similares